Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-07-11

Clinical Trial Update: Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ACER-001 (sodium phenylbutyrate) for treatment of Medium-chain Acyl-CoA Dehydrogenase Deficiency in pediatric and adult patients is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ACER-001 (sodium phenylbutyrate)

Snippet

Sponsor: Jerry Vockley, MD, PhD | Conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency | Phase 2 | Status: RECRUITING